Document:

Exhibit

CHIMERIX, INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

LAST MODIFIED: MARCH 29, 2016

Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Chimerix, Inc. (“Chimerix”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service.  This policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

Annual Cash Compensation

The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. 

		
	1.
	Annual Board Service Retainer: 

a.    All Eligible Directors: $35,000 

2.    Annual Committee Member Service Retainer:
a.    Member of the Audit Committee: $7,500 
b.    Member of the Compensation Committee: $5,000  
c.    Member of the Nominating & Corporate Governance Committee: $3,500 

3.    Annual Committee Chair Service Retainer (in lieu of Annual Committee Service Retainer):
a.    Chairman of the Audit Committee: $15,000 
b.    Chairman of the Compensation Committee: $10,000  
c.    Chairman of the Nominating & Corporate Governance Committee: $7,000 

Equity Compensation

The equity compensation set forth below will be granted under the Chimerix 2013 Equity Incentive Plan (the “Plan”). All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock of Chimerix (the “Common Stock”) on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).  Notwithstanding the foregoing, upon a termination of the Eligible Director’s Continuous Service other than for Cause (as such capitalized terms are defined in the Plan), the post-termination exercise period for all stock options granted under this policy shall be 

1.
 50791103 v6

(i) one year from the date of termination, if at the time of such termination the Eligible Director has served continuously on the Board for at least six years but less than nine years, (ii) two years from the date of termination, if at the time of such termination the Eligible Director has served continuously on the Board for at least nine years but less than twelve years, or (iii) three years from the date of termination, if at the time of such termination the Eligible Director has served continuously on the Board for at least twelve years, and in any of the foregoing (i) through (iii), subject to earlier termination pursuant to the ten year term of the option or as otherwise provided under the Plan.

1.    Initial Grant: On the date of the Eligible Director’s initial election to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase 18,000 shares.  One-fourth of the shares subject to the stock option will vest on the one year anniversary of the date of grant and the balance of the shares will vest in a series of 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

2.    Annual Grant: On the date of each Chimerix annual stockholder meeting, each Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase 9,000 shares. The shares subject to the stock option will vest in 12 equal monthly installments from the date of grant, provided that in any case each stock option is fully vested on the date of Chimerix’s next annual stockholder meeting, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through each such vesting date and provided further that the stock option will vest in full upon a Change in Control (as defined in the Plan).

3.    Chairman Grant: On the date of each Chimerix annual stockholder meeting, the chairman of the Board will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option having a Black-Scholes value of $25,000 on the date of grant.  The stock option will vest on the schedule set forth above for each annual grant.  Alternatively, at the written election of the chairman of the Board prior to the beginning of the applicable year, the chairman may receive in lieu of all or a portion of such option grant a cash service retainer paid on the schedule set forth above for each annual retainer.

2.
 50791103 v6Exhibit

	
															
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1.   CONTRACT ID CODE
	 PAGE   OF   PAGES

	1
	2
	 

	2.  AMENDMENT/MODIFICATION NO.
	3.  EFFECTIVE DATE
	4.  REQUISITION/PURCHASE REQ. NO.
	 5.  PROJECT NO. (if applicable)

	0035
	See Block 16C
	N/A
	 

	6.  ISSUED BY
	CODE
	ASPR-BARDA
	7.  ADMINISTERED BY (If other than Item 6)

	CODE
	ASPR-BARDA02

	ASPR-BARDA
200 Independence Ave., S.W.
Room 640-G
Washington DC 20201

	ASPR-BARDA
330 Independence Ave, SW, Rm G640
Washington DC 20201

	8.  NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
	(x)
	9A.  AMENDMENT OF SOLICITATION NO.

	

CHIMERIX, INC. 1377270
CHIMERIX, INC.   2505   MERIDIAN P
2505 MERIDIAN PKWY STE 340
DURHAM NC 277135246
	 
	 

	 9B.  DATED (SEE ITEM 11)

	 
	 

	x
	 10A.  MODIFICATION OF CONTRACT/ORDER NO.
 HHSO100201100013C

	 

	 10B.  DATED (SEE ITEM 13)
02/16/2011

	CODE 
1377270
	FACILITY CODE   
	 

	11.  THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	o   The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers   o  is extended.    o is not extended
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning ___________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12.  ACCOUNTING AND APPROPRIATION DATA (if required)
N/A                                                                                                     Net Increase: 

	13.  THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK ONE
	A.   THIS CHANGE ORDER IS ISSUED PURSUANT TO:  (Specify authority)  THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 

	 
	B.   THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

	 
	C.   THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

	X
	D.   OTHER (Specify type of modification and authority)
Bilateral:  Mutual Agreement of the Parties.

	E.  IMPORTANT:   Contractor   o  is not.   x  is required to sign this document and return            0    copies to the issuing office.

	14.  DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

	Tax ID Number:    33-0903395
DUNS Number:    121785997

A. The purpose of this modification is to incorporate the following changes into the
contract:

1. The period of performance for CLIN 0004 of Contract Number HHS0100201100013C ONLY is
hereby changed from 11 September 2015 through 31 October 2016 to 11 September 2015 through
31 January 2017, at no additional cost to the Government. The total amount and scope of
CLIN 0004 of Contract Number HHS0100201100013C remains unchanged.

2. The total amount, scope and period of performance of all other CLINs that are currently 
Continued...

	Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15A.  NAME AND TITLE OF SIGNER (Type or print)
	 16A.  NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

	Timothy W. Trost, SVP & CFO
	ETHAN J. MUELLER

	15B.  CONTRACTOR/OFFEROR
	15C.  DATE SIGNED
	16B.  UNITED STATES OF AMERICA
	16C.  DATE SIGNED

	   /s/ Timothy W. Trost  
       (Signature of person authorized to sign)
	10/20/2016
	   /s/ Ethan J. Mueller    
             (Signature of Contracting Officer)
	10/21/2016

NSN 7540-01-152-8070                                    STANDARD FORM 30 (REV. 10-83)
Previous edition unusable                                    Prescribed by GSA
FAR (48 CFR) 53.243

	
									
	CONTINUATION SHEET
	REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201100013C/0035
	PAGE   OF

	2
	2

	NAME OF OFFEROR OR CONTACTOR
CHIMERIX, INC. 1377270

	ITEM NO.
(A)
	SUPPLIES/SERVICES
(B)
	QUANTITY
(C)
	UNIT
(D)
	UNIT PRICE
(E)
	AMOUNT
(F)

	 
	being performed under the contract remain unchanged. This modification does not
exercise any unexercised Option CLINs under the contract and does not authorize any
performance of efforts under any unexercised Option CLINs under the contract. In
addition, the total amount, scope and period of performance of all unexercised
Option CLINs under the contract remain unchanged. This modification also confirms
that all activities under the base period of performance CLIN 0001 were completed as
of 31 May 2013 and confirms that all activities under the Option l/CLIN 0002 period
of performance were completed as of 30 April 2015.

B. This is a no cost bilateral modification. All other terms and conditions of
Contract Number HHSO100201100013C remain unchanged.

Period of Performance: 02/16/2011 to 06/30/2017

NSN 7540-01-152-8067                                        OPTIONAL FORM 336 (4-86)
                                             Sponsored by GSA
FAR (48 CFR) 53.110

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]